{"id":1000246,"date":"2026-09-03T10:35:54","date_gmt":"2026-09-03T14:35:54","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/"},"modified":"2026-09-03T10:35:54","modified_gmt":"2026-09-03T14:35:54","slug":"nuvectis-pharma-to-participate-in-upcoming-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/","title":{"rendered":"Nuvectis Pharma To Participate in Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>Fort Lee, NJ, Sept.  03, 2026  (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences:<\/p>\n<ul>\n<li style=\"margin-top:0in;margin-bottom:0in\">\n          <b>2026 Cantor Global Healthcare Conference:<\/b> Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast link: <a href=\"https:\/\/sqps.onstreamsecure.com\/origin\/enliven\/players\/EnlivenPlayer.html?customerId=22&amp;eventId=40110723&amp;checkCompany=1&amp;checkEmail=1&amp;checkName=1\" rel=\"nofollow\" target=\"_blank\">Cantor Fireside Chat<\/a>.<\/li>\n<li style=\"margin-top:6pt;margin-bottom:6pt\">\n          <b>H.C. Wainwright 28<sup>th<\/sup> Annual Global Investment Conference:<\/b> Company Presentation, Monday, September 14, 2026 at 12:00 PM ET. Webcast link: <a href=\"https:\/\/journey.ct.events\/view\/78ef9fa6-0343-48ce-b48c-59f7cd3bfc77\" rel=\"nofollow\" target=\"_blank\">Nuvectis Presentation<\/a>.<\/li>\n<\/ul>\n<p>A webcast of the presentations will be available in the Investors section of Nuvectis\u2019 website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=QRXHqV14yUKdjfSmZRzm6GeG9xqP32i1D-zuovwNL0jW9VuC1b9urB41R1G0x_AFzw6lM-j-LcCBy8S_Hu8zXjrkFzMUEvRqLCSog6tMuKI=\" rel=\"nofollow\" target=\"_blank\">www.nuvectis.com<\/a>.<\/p>\n<p>\n        <b>About Nuvectis Pharma, Inc.<\/b>\n      <\/p>\n<p>Nuvectis Pharma, Inc. is a clinical stage biopharmaceutical company focused on the development of innovative therapies for the treatment of immune complement-related conditions and oncology. The Company\u2019s pipeline includes ciprocopan (NXP100), a complement Factor B inhibitor in development for the treatment of complement-mediated diseases, and the oncology drug candidates NXP900 and NXP200, in development for the treatment of advanced cancers.<\/p>\n<p>The company\u2019s lead drug candidate is ciprocopan, a Factor B inhibitor, with best-in-class potential, recently approved in China for the treatment of PNH patients previously untreated with complement inhibitors. In PNH and other complement-mediated diseases, ciprocopan is expected to provide a meaningful convenience advantage as a once-daily, oral treatment option for diseases requiring lifelong treatment.<\/p>\n<p>NXP200 is an oral, brain-penetrant, paradox-breaker BRAF inhibitor for the treatment of BRAF V600X-mutated and Class II\/III non-V600-mutated solid tumor malignancies, including central nervous system cancer, colorectal cancer, melanoma, and non-small cell lung cancer, with best-in-class potential.<\/p>\n<p>NXP900 is an oral small molecule inhibitor of the SRC Family of Kinases, including SRC and YES1 intended to inhibit the catalytic and scaffolding functions of the SRC kinase, providing comprehensive shutdown of the SRC signaling pathway.<\/p>\n<p align=\"justify\">\n        <b>Company Contact<\/b>\n      <\/p>\n<p align=\"justify\">Ron Bentsur<br \/>Chairman, Chief Executive Officer and President <br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gty-g7-N7ZimvsN1Mc5UxlCe4E0ExCWfojMaZMb8oh9bGhk1pcFUuXlJnjDw6AEffjPtnSW7VaBR8INzwCa0_O-1was8K5g7m2B12vSPvPQ=\" rel=\"nofollow\" target=\"_blank\">rbentsur@nuvectis.com<\/a><\/p>\n<p align=\"justify\">\n        <b>Media Relations Contact<\/b>\n      <\/p>\n<p align=\"justify\">Kevin Gardner<br \/>LifeSci Advisors<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rcIVL1nYGvhv6A-aD5OMAi-5QiE1eL2Nxd90kWrUUOHwn_vhhoo70DA7LGzs1sXtCXXlJkNkVm4H57PWPV3qJApO_js-N3RSmZ4AFvis4FQnLwf0WHYAkwWiDzEE57mC\" rel=\"nofollow\" target=\"_blank\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/OTI2YjhjMzUtNTAzYS00MjUwLWEyNWMtMWZlM2U1YTFlOGViLTUwMDA4MjgxNy0yMDI2LTA5LTAzLWVu\/tiny\/Nuvectis-Pharma-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast link: Cantor Fireside Chat. H.C. Wainwright 28th Annual Global Investment Conference: Company Presentation, Monday, September 14, 2026 at 12:00 PM ET. Webcast link: Nuvectis Presentation. A webcast of the presentations will be available in the Investors section of Nuvectis\u2019 website at www.nuvectis.com. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a clinical &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Nuvectis Pharma To Participate in Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1000246","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nuvectis Pharma To Participate in Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nuvectis Pharma To Participate in Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast link: Cantor Fireside Chat. H.C. Wainwright 28th Annual Global Investment Conference: Company Presentation, Monday, September 14, 2026 at 12:00 PM ET. Webcast link: Nuvectis Presentation. A webcast of the presentations will be available in the Investors section of Nuvectis\u2019 website at www.nuvectis.com. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a clinical &hellip; Continue reading &quot;Nuvectis Pharma To Participate in Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-03T14:35:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Nuvectis Pharma To Participate in Upcoming Investor Conferences\",\"datePublished\":\"2026-09-03T14:35:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/\"},\"wordCount\":331,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/\",\"name\":\"Nuvectis Pharma To Participate in Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==\",\"datePublished\":\"2026-09-03T14:35:54+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nuvectis Pharma To Participate in Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nuvectis Pharma To Participate in Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Nuvectis Pharma To Participate in Upcoming Investor Conferences - Market Newsdesk","og_description":"Fort Lee, NJ, Sept. 03, 2026 (GLOBE NEWSWIRE) &#8212; Nuvectis Pharma, Inc. (NASDAQ: NVCT) (&#8220;Nuvectis&#8221; or the &#8220;Company&#8221;), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the following upcoming investor conferences: 2026 Cantor Global Healthcare Conference: Fireside Chat, Friday, September 11, 2026 at 9:10 AM ET. Webcast link: Cantor Fireside Chat. H.C. Wainwright 28th Annual Global Investment Conference: Company Presentation, Monday, September 14, 2026 at 12:00 PM ET. Webcast link: Nuvectis Presentation. A webcast of the presentations will be available in the Investors section of Nuvectis\u2019 website at www.nuvectis.com. About Nuvectis Pharma, Inc. Nuvectis Pharma, Inc. is a clinical &hellip; Continue reading \"Nuvectis Pharma To Participate in Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-03T14:35:54+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Nuvectis Pharma To Participate in Upcoming Investor Conferences","datePublished":"2026-09-03T14:35:54+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/"},"wordCount":331,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/","name":"Nuvectis Pharma To Participate in Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==","datePublished":"2026-09-03T14:35:54+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTgyMDY0NCM3ODE2MDgzIzUwMDA4MjgxNw=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/nuvectis-pharma-to-participate-in-upcoming-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Nuvectis Pharma To Participate in Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000246","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1000246"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1000246\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1000246"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1000246"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1000246"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}